Hannah Frazer1, Jingjing You1,2, Chris Hodge3,4, Con Petsoglou1,4,5, Pierre Georges4, Adam Taylor6, Gordon Wallace6, Gerard Sutton1,3,4
Purpose: Corneal injuries represent the most com- mon ophthalmic emergency presentation in Australia. We have previously developed a novel bioink (iFixInk) that is transparent, biocompatible, biodegradable, 3D-printable and sets in 2 minutes, and have shown that it promotes wound healing in an in vitro model. We aimed to test this in an ex vivo model and its ability to act as a cell carrier. Methods: Ulcerated corneas were debrided and sus- pended in organ culture media. iFixInk was extruded onto the debrided surface at days 1 and 4 (n = 3). The corneas were ﬁxed at day 7, cryosec- tioned and compared to control ulcerated corneas kept in the same conditions but not to the iFixInk (n = 3). The sections were stained with H&E to examine for epithelial morphology.
P18 HCET cells were trypsinised and suspended in the iFixInk and extruded in a petri dish. Another layer was then extruded orthogonally on top. Hoechst and Propidium Iodide live-dead staining were performed at 2 and 72 hours post extrusion and analyzed using Image J.
Results: Epithelial regeneration was observed in iFixInk treated corneas and not in the controls. HCET cells exhibited over 90% cell viability post extrusion and can be printed into distinct, stackable layers.
Conclusion: These preliminary results demonstrate that iFixInk can be used for cell-printing and encourages wound-healing in an ex vivo model. This could potentially serve as a treatment for cor- neal injuries, increase the pool of suitable donor cor- neas and also serve as a foundation for 3D printing artiﬁcial corneas in the future.
COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A ?TREAT AND EXTEND? PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12- MONTH INTERIM ANALYSIS OF THE RIVAL STUDY